Home › Research › Biomarkers
Plasma p-tau217 concordance with amyloid PET among ethnically diverse older adults
Breton M Asken, Jesse C DeSimone, Wei-En Wang, Karen N McFarland, Franchesca Arias, Shellie-Anne Levy, Jacob Fiala, Idaly Velez-Uribe et al.. Alzheimer's & dementia (Amsterdam, Netherlands), 2024-07-17
Topic: Plasma and spinal-fluid biomarkers
A total of 239 participants underwent blood draw and Aβ-PET (age 70.8 ± 7.8, 55.2% female, education 15.6 ± 3.4 years, 48.9% Hispanic/Latino, 94.9% white). Plasma p-tau217 showed excellent discrimination of Aβ-PET positive and negative participants (visual read: AUC = 0.91 [0.87-0.95], p < 0.001; Centiloids quantification: AUC = 0.90 [0.86-0.94]). There was a greater percent agreement between low p-tau217 and negative Aβ-PET (95.8%) than high p-tau217 and positive Aβ-PET (86.3%). Analyses within ethnicity-specific subgroups suggested similar p-tau217 performance. Plasma p-tau217 (ALZPath) relates to brain Aβ in Hispanic/Latino and non-Hispanic/Latino older adults. Independent validation and replication are necessary to establish reference ranges and inform appropriate contexts of use across ethno-racially diverse populations. HIGHLIGHTS: Plasma p-tau217 (ALZPath) and Aβ-PET were measured in Hispanic/Latino and non-Hispanic/Latino older adults.Plasma p-tau217 accurately discriminated Aβ-PET positive and negative participants.Applying a two-cutoff "intermediate" plasma p-tau217 approach could reduce need for more invasive and costly testing.Plasma p-tau217 associations with Aβ-PET were strong within both Hispanic/Latino and non-Hispanic/Latino groups.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Asken, B. M., DeSimone, J. C., Wang, W.-E., McFarland, K. N., Arias, F., Levy, S.-A., et al. (2024). Plasma p-tau217 concordance with amyloid PET among ethnically diverse older adults. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1002/dad2.12617
Vancouver
Asken BM, DeSimone JC, Wang W.-E, McFarland KN, Arias F, Levy S.-A, et al. Plasma p-tau217 concordance with amyloid PET among ethnically diverse older adults. Alzheimer's & dementia (Amsterdam, Netherlands). 2024. doi:10.1002/dad2.12617. PMID: 39021585.
BibTeX
@article{asken2024-39021585,
author = {Asken, Breton M and DeSimone, Jesse C and Wang, Wei-En and McFarland, Karen N and Arias, Franchesca and Levy, Shellie-Anne and Fiala, Jacob and Velez-Uribe, Idaly and others},
title = {{Plasma p-tau217 concordance with amyloid PET among ethnically diverse older adults}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2024},
doi = {10.1002/dad2.12617},
pmid = {39021585},
url = {https://doi.org/10.1002/dad2.12617}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- A total of 239 participants underwent blood draw and Aβ-PET (age 70.8 ± 7.8, 55.2% female, education 15.6 ± 3.4 years, 48.9% Hispanic/Latino, 94.9% white).
- Plasma p-tau217 showed excellent discrimination of Aβ-PET positive and negative participants (visual read: AUC = 0.91 [0.87-0.95], p < 0.001; Centiloids quantification: AUC = 0.90 [0.86-0.94]).
- There was a greater percent agreement between low p-tau217 and negative Aβ-PET (95.8%) than high p-tau217 and positive Aβ-PET (86.3%).
- Analyses within ethnicity-specific subgroups suggested similar p-tau217 performance.
- Plasma p-tau217 (ALZPath) relates to brain Aβ in Hispanic/Latino and non-Hispanic/Latino older adults.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants239
- Effect size55.2%; 48.9%; 94.9%
- Evidence strengthLow
How this study scored 59/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 33 of the 56 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 239 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39021585) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 33 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 33 of the 56 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers
Also tagged “18f”
318 studies in the library carry the topic tag “18f”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 318 tagged studies.